These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20881928)

  • 1. Mayo Clinic office visit. NSAIDs and cardiovascular risks. An interview with Sharon Mulvagh, M.D.
    Mulvagh S
    Mayo Clin Womens Healthsource; 2010 Nov; 14(11):6. PubMed ID: 20881928
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.
    Hermann M; Ruschitzka F
    Ann Med; 2007; 39(1):18-27. PubMed ID: 17364448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cardiovascular toxicity of selective COX-2-inhibitors and classical NSAIDs].
    Lange H; Eberhart L
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2007 Jul; 42(7):514-7. PubMed ID: 17661262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular adverse reactions from NSAIDs are more than COX-2 inhibition alone.
    Rainsford KD
    Rheumatology (Oxford); 2010 May; 49(5):834-6. PubMed ID: 20097907
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiovascular risks of cyclooxygenase inhibition.
    Stacy ZA; Dobesh PP; Trujillo TC
    Pharmacotherapy; 2006 Jul; 26(7):919-38. PubMed ID: 16803424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balancing risks and benefits of cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs.
    Scheiman JM
    Gastroenterol Clin North Am; 2009 Jun; 38(2):305-14. PubMed ID: 19446260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk.
    Vardeny O; Solomon SD
    Cardiol Clin; 2008 Nov; 26(4):589-601. PubMed ID: 18929233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs].
    van den Bemt BJ; Benraad HB; Rasker JJ
    Ned Tijdschr Geneeskd; 2007 May; 151(19):1062-7. PubMed ID: 17552414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular issues of COX-2 inhibitors and NSAIDs.
    Wong M; Chowienczyk P; Kirkham B
    Aust Fam Physician; 2005 Nov; 34(11):945-8. PubMed ID: 16299629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk.
    Woodruff T
    Intern Med J; 2006 Dec; 36(12):797-8; author reply 798-9. PubMed ID: 17096747
    [No Abstract]   [Full Text] [Related]  

  • 13. The practice implications of cardiovascular risks in NSAIDs.
    Hainsworth T
    Nurs Times; 2005 Jun 28-Jul 4; 101(26):26-7. PubMed ID: 16010838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug safety of NSAIDs and COX-2 inhibitors].
    Herdegen T; Fauler J
    Med Monatsschr Pharm; 2006 Apr; 29(4):122-8. PubMed ID: 16628961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NSAIDs and cardiovascular disease.
    Patrignani P; Capone ML; Tacconelli S
    Heart; 2008 Apr; 94(4):395-7. PubMed ID: 18347364
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.
    Joshi GP; Gertler R; Fricker R
    Anesth Analg; 2007 Dec; 105(6):1793-804, table of contents. PubMed ID: 18042885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk.
    Hermann M; Ruschitzka F
    Intern Med J; 2006 May; 36(5):308-19. PubMed ID: 16650196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis and recommendations for agency action regarding nonsteroidal antiinflammatory drugs and cardiovascular risk.
    U.S. Food and Drug Administration
    J Pain Palliat Care Pharmacother; 2005; 19(4):83-97. PubMed ID: 16431839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Further definition of the role of COX-2 inhibitors and NSAIDs in patients with nociceptive pain].
    Nurmohamed MT
    Ned Tijdschr Geneeskd; 2007 Jun; 151(23):1313; author reply 1313-4. PubMed ID: 17624165
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.